The discovery of potent antagonists of NPBWR1 (GPR7)

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1014-8. doi: 10.1016/j.bmcl.2011.11.126. Epub 2011 Dec 8.

Abstract

The synthesis and evaluation of small molecule antagonists of the G protein-coupled receptor NPBWR1 (GPR7) are reported for the first time. [4-(5-Chloropyridin-2-yl)piperazin-1-yl][(1S,2S,4R)-4-{[(1R)-1-(4-methoxyphenyl)ethyl]amino}-2-(thiophen-3-yl)cyclohexyl]methanone (1) emerged as a hit from a high-throughput screen. Examination of substituents that focused on replacing the 5-chloropyridine and 4-methoxybenzylamino groups of 1 led to the identification of compounds that exhibited subnanomolar potencies as low as 660pM (9k) in the functional assay and 200pM in the binding assay (9i).

MeSH terms

  • Animals
  • Benzylamines / chemical synthesis
  • Benzylamines / chemistry
  • Benzylamines / pharmacology*
  • Crystallography, X-Ray
  • Dose-Response Relationship, Drug
  • Humans
  • Mice
  • Models, Molecular
  • Molecular Structure
  • Piperazine
  • Piperazines / chemical synthesis
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Receptors, G-Protein-Coupled / antagonists & inhibitors*
  • Receptors, Neuropeptide / antagonists & inhibitors*
  • Stereoisomerism
  • Structure-Activity Relationship

Substances

  • Benzylamines
  • NPBWR1 protein, human
  • Npbwr1 protein, mouse
  • Piperazines
  • Receptors, G-Protein-Coupled
  • Receptors, Neuropeptide
  • Piperazine
  • benzylamine